摘要
异常血管新生是多种视网膜疾病的病理性标志。血管内皮生长因子(VEGF)主要调控内皮细胞的增生与迁移,VEGF受体2(VEGFR2)是介导这一作用的主要受体,下游信号的激活首先需要VEGF与VEGFR2结合,随后发生受体二聚体化和自磷酸化,阻断这一过程进而抑制新生血管的形成是一个非常具有吸引力的治疗策略。眼科临床目前应用的单克隆抗体和融合蛋白药物主要结合游离的VEGF,随着拮抗VEGFR2的大分子抗体和小分子酪氨酸激酶抑制剂的药物上市,有望进一步拓展至眼科领域。抗VEGFR2治疗虽是抑制新生血管的革命性方法,但目前尚无充足的临床证据。深入了解抗VEGFR2治疗视网膜新生血管疾病的应用现状及进展具有重要的临床意义。
Neovascularization is a characteristic manifestation of a variety of retinal diseases.Vascular endothelial growth factor(VEGF)mainly regulates the proliferation and migration of endothelial cells.VEGF receptor 2(VEGFR2)is the main receptor to mediate this effect.The activation of downstream signals requires the binding of VEGF and VEGFR2,followed by receptor dimerization and autophosphorylation.Blocking this process and inhibiting neovascularization is very attractive treatment ideas.Monoclonal antibodies and fusion protein drugs currently used in ophthalmology can bind free VEGF.In addition,there are also macromolecular antibodies binding VEGFR2 and small molecule tyrosine kinase inhibitors,which is expected to further expand into the field of ophthalmology.Although anti-VEGFR2 therapy is a revolutionary method to inhibit neovascularization,there are no sufficient clinical evidences at present.In-depth understanding of the application status and progress of anti-VEGFR2 in the treatment of retinal neovascular diseases has important clinical significance.
作者
张明亮
杨宋阳
胡岚岚
李筱荣
Zhang Mingliang;Yang Songyang;Hu Lanlan;Li Xiaorong(Tianjin Key Laboratory of Retinal Functions and Diseases,Tianjin Branch of National Clinical Research Center for Ocular Disease,Eye Institute and School of Optometry,Tianjin Medical University Eye Hospital,Tianjin 300384,China)
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2021年第7期562-566,共5页
Chinese Journal of Ocular Fundus Diseases
基金
国家自然科学基金青年项目(81900894)
天津市自然科学基金青年项目(18JCQNJC11300)
天津市临床重点学科(专科)建设项目(TJLCZDXKQ004)
天津市视网膜功能与疾病重点实验室自主与开放课题(2019tjswmm004)。
关键词
受体
血管内皮生长因子
视网膜新生血管化
综述
Receptors,vascular endothelial growth factor
Retinal neovascularization
Review
